a
a
Weather:
No weather information available
Home2025Marzo (Page 511)

The preliminary IPO papers were received by the Securities and Exchange Board of India (Sebi) on February 13, however, "draft

The preliminary IPO papers were received by the Securities and Exchange Board of India (Sebi) on February 13, however, "draft

Nature Medicine, Published online: 26 March 2025; doi:10.1038/s41591-025-03551-8Rwanda’s science-led response to Marburg virus holds lessons for other outbreaks in Africa

Nature Medicine, Published online: 26 March 2025; doi:10.1038/s41591-025-03587-wDespite bringing great strengths and facing substantial health inequities, disabled people remain underserved

Nature Medicine, Published online: 26 March 2025; doi:10.1038/s41591-025-03605-xIn a community-based cohort of more than 2,000 older adults from Sweden, blood

13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March

Leap to host a conference call to present updated CRC clinical data today, March 26, 2025, at 8:00 a.m. ET

New Clinical Data from Phase 2 Trial of LUT014 for the Treatment of Patients With EGFRI-Induced Acneiform Rash Accepted for

CAMBRIDGE, Mass., March 26, 2025 /PRNewswire/ -- Auregen Biotherapeutics, a clinical-stage company developing precision approaches to restore functional anatomy with

Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1

Translate »